MIL62 plus lenalidomide for relapsed follicular or MZ lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-stage study tests whether MIL62 combined with lenalidomide can shrink or control follicular lymphoma or marginal zone (MZ) lymphoma that has come back or not responded to earlier treatment. It’s designed for adults with measurable disease and enough body strength to take part.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older
- You have confirmed follicular lymphoma (grade 1–3a) or marginal zone lymphoma that is CD20-positive
- Your lymphoma is getting worse or hasn’t responded after at least one earlier treatment
- Your scans show at least one measurable lymph node or tumor (CT: long side over 1.5 cm and short side at least 10 mm)
- Your general health is good enough (ECOG performance status 0–2)
- You can have blood tests showing enough blood function and you expect to live more than 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding MIL62 to lenalidomide works better than lenalidomide alone in people with follicular lymphoma that no longer responds to rituximab. The goal is to improve tumor control by using an additional medicine along with standard treatment.
This trial studies whether obinutuzumab combined with lenalidomide can control marginal zone lymphoma that has come back or not responded to prior treatment. If you qualify, you may receive these medicines together to help shrink tumors and improve symptoms.
This trial tests a new drug, IMM0306, combined with lenalidomide for people with follicular lymphoma that has come back or stopped responding to at least two prior treatments. The goal is to see if adding IMM0306 helps more than lenalidomide alone.
This trial tests a new drug called SCTB35 combined with lenalidomide (a known cancer drug) in people whose follicular lymphoma (a type of blood cancer) has stopped responding to or come back after previous treatments. The combination may help shrink tumors and improve survival.
This study looks at giving obinutuzumab together with lenalidomide to adults whose follicular lymphoma has come back or did not respond well to prior treatment. It may help control the cancer after relapse or resistance to standard therapies.
This trial tests whether a new drug, odronextamab, combined with lenalidomide works better than the current standard, rituximab combined with lenalidomide, for people whose follicular or marginal zone lymphoma has come back or not responded to prior treatment. It aims to see which combo is safer and more effective.
Hear when a new Follicular Lymphoma and Marginal Zone Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.